Dr. Van Ameringen reports being on the Advisory Boards of Allergan, Almatica, Brainsway, Lundbeck, Myriad Neuroscience, Otsuka, Purdue Pharma (Canada), Tilray and Vistagen; he is on the Speaker's Bureau for Allergan, Lundbeck, Purdue Pharma (Canada), and Takeda; he has received research support from Purdue Pharma (Canada), the Canadian institute for Health Research and Hamilton Academic Health Sciences Organization (HAHSO) and honoraria from UpToDate; and leadership roles at the International College of Obsessive Compulsive Spectrum Disorders (unpaid) outside the submitted work.
Ms. Patterson has nothing to disclose.
Dr. Turna has nothing to disclose.
Ms. Lethbridge has nothing to disclose.
Dr. Goldman Bergmann has nothing to disclose.
Ms. Lamberti has nothing to disclose.
Ms. Rahat has nothing to disclose.
Ms. Sideris has nothing to disclose.
Dr. Francisco has nothing to disclose.
Prof. Fineberg reports research funding from the National Institute for Health Research and COST Action; royalties from Oxford University Press; support for attending meetings/travel from the European college of Neuropsychopharmacology COST Action, International Forum of Mod and Anxiety disorders, British Association for Psychopharmacology, Royal College of Psychiatrists and the World Psychiatric Association; leadership roles at the International College of Obsessive Compulsive Spectrum Disorders (unpaid), MHRA and Orchard; she also leads an NHS treatment service for OCD, focusing on psychopharmacology and publishes on OCD treatments including psychopharmacology, all outside of the submitted work.
Prof. Pallanti reports grant funding from NIH R21; consulting fees from Recordati, Angelini Pharma, GW Research Limited, Octapharma, SAGE Therapeutics INC, Biohaven Pharmaceuticals Inc and Gideon Ritcher PLC, all outside of the submitted work.
Prof. Grassi has nothing to disclose.
Prof. Vismara has nothing to disclose.
Prof. Albert reports consulting fees from Angelini and Bohrenger; honoraria from Lundbeck, Neuraxpharm and Janssen-Cilag; and advisory board participation for Janssen-Cilag, Angelini and Lundbeck all outside of the submitted work.
Dr. Gedanke Shavitt reports grant funding from the National Council for Scientific and Technological Development; honoraria from Lundbeck; and travel support from Lundbeck and Libbs all outside of the submitted work.
Dr. Hollander reports grants from the Department of Defense, Orphan Products – FDA and Roche; royalties from the American Psychiatry Association and Elsevier; consulting fees from Roche and GW Pharma; honoraria from Sunovian; participation on a Data Safety Monitoring Board or Advisory Board for Roche and GW Pharma; and a leadership role at the International College of Obsessive Compulsive Spectrum Disorders (unpaid), all outside of the submitted work.
Dr. Feusner reports consulting fees and stock options from NOCD Inc, and a leadership role at the International College of Obsessive Compulsive Spectrum Disorders (unpaid), all outside of the submitted work.
Dr. Rodriguez has received research grant support from Biohaven Pharmaceuticals; has served as a consultant for Epiodyne and Biohaven Pharmaceuticals; and receives a stipend from APA Publishing for her role as Deputy Editor at The American Journal of Psychiatry, all outside of the submitted work.
Prof. Morgado reports receiving grants from FLAD, FCT and Fundação Calouste Gulbenkian; consulting fees from Janseen, Angelini, Lundbeck and Bial; honoraria from Astra Zeneca and Biogen as well as membership on the Board of Directors of Psychiatry of the Portuguese Medical Association, all outside of the submitted work.
Prof. Dell’Osso reports consulting fees from Lundbeck, Otsuka and Janssen; and honoraria from Lundbeck, Janssen, Pfizer, Otsuka, Angelini and Livanova, all outside of the submitted work.
